FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease
Written by
PharmaTimes
Published
0
comments
0
min
New subcutaneous autoinjector offers at-home treatment option for patients New subcutaneous autoinjector offers at-home treatment option for patients